Stay up to date with the latest research and clinical updates on bladder cancer from the 2025 American Society of Clinical Oncology Annual Meeting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
Drs. Galsky and Tawagi discuss the NIAGARA trial on perioperative durvalumab in combination with chemotherapy for MIBC.
Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis.
Drs. Galsky and Tawagi detail the event-free survival subgroup analyses based on disease stage from the CREST study.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.